Pharmaceutical Industry in
Epalinges

PRECLIN Biosystems SA

Since 2008 · 1–10 empl.

PRECLIN Biosystems SA provides a comprehensive in vivo preclinical testing platform for the identification and validation of lead therapeutic candidates and specializes in preclinical models of chronic inflammatory and infectious diseases.

NovaPharm SA

Since 2008 · 1–10 empl.

NovaPharm SA provides consulting, services and trading in the healthcare sector, including market access, distribution, sourcing and regulatory compliance. The company conducts purchase and resale of medicines and health products and holds a Swissmedic authorization for trading.

Combioxin SA

Since 2015 · 11–20 empl.

The core activity of Combioxin SA is the development of life-saving medications for severe infections, particularly for the treatment of severe bacterial pneumonias. The company focuses on the development of innovative therapeutics, such as CAL02, a first-in-class anti-toxin agent used to neutralize virulence factors that play a crucial role in the development of organ failure and fatal complications in severe infections.

LAM Biotechnologies SA

Since 2018 · 1–10 empl.

LAM Biotechnologies SA is a biotechnology company focused on research and development, production of its own products, and sales and marketing of those products. It also provides services in diagnostics, platform technologies, analytical testing, screening, and bioinformatics.

Haya Therapeutics SA

Since 2019 · 21–50 empl.

The company develops precise therapeutics based on genome research and biotechnology. It focuses on the development of medicines and therapies, particularly in the field of cardiovascular diseases and regenerative medicine. The core activity includes research and development of new medicines, identification and evaluation of new business opportunities, conducting due diligence reviews, and managing portfolio companies.

Onward Therapeutics SA

Since 2019 · 1–10 empl.

The core activity of Onward Therapeutics is the development of innovative cancer treatments, particularly through the identification and development of potential active substances and technologies in the field of immunotherapy and oncology. The company focuses on the development of drugs that support the immune system to fight cancer, and works with partners to develop and market transformative technologies.

Vandria SA

Since 2021 · 21–50 empl.

Vandria SA is a clinical-stage biotech company developing first-in-class small molecules against a novel metabolic target to restore mitochondrial function and reduce chronic inflammation for the treatment of age-related and chronic diseases. Its lead clinical CNS asset, VNA-318, is an orally available, brain-penetrant small molecule that completed Phase I studies demonstrating safety, tolerability and a pharmacokinetic profile suitable for once-daily oral dosing.

Dorphan SA

Since 2011 · 1–10 empl.

PDC Therapeutics SA

Since 2020 · 1–10 empl.

The core activity of PDC Therapeutics is the development of targeted polymer-drug conjugate technologies and smart nanomedicines for targeted therapies, particularly using the proprietary Sagitta biodegradation platform, to offer patients an optimal therapeutic ratio.

ADC Therapeutics SA

Since 2011 · 11–20 empl.·5.0(1)

The core activity of ADC Therapeutics SA is the development and manufacturing of antibody-drug conjugates (ADCs), particularly for the treatment of cancer.

Legacy Healthcare (Switzerland) SA

Since 2007 · 21–50 empl.·1.0(1)

Legacy Healthcare (Switzerland) SA is a biopharmaceutical company that develops prescription botanical drugs for autoimmune and inflammatory conditions. Its lead product candidate, CINAINU, is a topical botanical formulation that showed superiority to placebo in a phase 2/3 study (RAAINBOW) in moderate and severe alopecia areata and is being advanced through clinical and regulatory programs.

Exogems SA

Since 2022 · 1–10 empl.

Exogems SA is a Swiss biotech company developing exosome-based therapeutics for inflammation and regenerative medicine. The company works with the Lipogems® platform and proprietary technology to isolate and produce clinical-grade exosomes from adipose tissue.